Actuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-13 · Company identity, CIK, ticker, exchange, headquarters, and filing sequence.SEC APISEC companyfacts JSON2026-05-13 · XBRL financial fact cross-check support.SEC filingFY2025 Form 10-K2026-03-26 · Business model, elraglusib program, annual financials, going-concern risk, risk factors, licenses, competition, IPO and financing.SEC filingQ3 2025 Form 10-Q2025-11-13 · Latest quarterly report available before FY2025 annual filing; cash and operating context.SEC-filed releaseOral elraglusib IND release2026-05-11 · FDA IND clearance, oral elraglusib Phase 1/2 plan, EMA/FDA path, and financing-warning language.SEC-filed presentationMay 2026 corporate presentation2026-05-11 · Pipeline map, exposure rationale, oral tablet strategy, pediatric oncology plan, leadership, and development timeline.SEC-filed releaseASCO GI data release2026-01-12 · Phase 2 mPDAC survival, safety, biomarkers, and trial design.SEC filing2026 proxy statement2026-04-06 · Annual meeting, board, record-date shares, governance, and ownership context.Government trial registryClinicalTrials.gov NCT036788832026-05-13 · Actuate-1801 / 9-ING-41 trial status, conditions, interventions, and dates.Government trial registryClinicalTrials.gov NCT068961882026-05-13 · RiLEY investigator-initiated trial status and regimen.